Team members from Kessler Foundation and Kessler Institute for Rehabilitation, a Select Medical hospital, will participate in an EMAGINE 2.0 study, a trial to evaluate non-invasive brain stimulation for upper-extremity disability post-stroke. This study seeks…
A federal judge in North Dakota has ruled in favor of 19 states that challenged a Biden administration rule allowing — for the first time — enrollment in Affordable Care Act coverage…
Juana Valle never imagined she’d be scared to drink water from her tap or eat fresh eggs and walnuts when she bought her 5-acre farm in San Juan Bautista, California, three years…
Not only are they the smallest among us, premature children also face health and life challenges that make them the most vulnerable. Generally speaking, they have a slightly higher risk of mortality…
Petrovax announced today the positive results from “Long-CoV-III-21,” a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19. Bovhyaluronidase azoximer, marketed…
A specific brain mechanism modulates how animals respond empathetically to others’ emotions. This is the latest finding from the research unit Genetics of Cognition, led by Francesco Papaleo, Principal Investigator at the…
DILI is broadly categorized into intrinsic and idiosyncratic types. Intrinsic hepatotoxins, such as APAP, cause dose-dependent injury, while idiosyncratic DILI involves complex immune and metabolic interactions that remain poorly understood. Mechanistic studies…
Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known…
Researchers at DTU have succeeded in developing a natural and simple method for producing vitamin B2: by gently heating lactic acid bacteria. This could be a game-changer in developing countries, where many…
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer—as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib…
